✦ LIBER ✦

Safety, compliance and the effects on memory of 48-week Souvenaid use in mild Alzheimer's disease: Results from the Souvenir II and open-label extension study

✍ Scribed by Scheltens, Philip; Twisk, Jos; Blesa, Rafael; Scarpini, Elio; von Arnim, Christine; Bongers, Anke; Harrison, John; Swinkels, Sophie; Wurtman, Richard; Wieggers, R.L.; Vellas, Bruno; Kamphuis, Patrick

Book ID: 122123989
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 73 KB
Volume: 8
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2013.08.130

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Open label, multicenter, 28-week extensi

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

✍ Brian R. Ott; Lesley M. Blake; Ethel Kagan; Malca Resnick; for the Memantine MEM 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 142 KB

P.4.006 Long-term efficacy and safety be

P.4.006 Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease

✍ H.-J. Moebius; B. Reisberg; F. Schmitt; R. Doody 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 274 KB

Long-term efficacy and safety of donepez

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

✍ S.L Rogers; L.T Friedhoff 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 303 KB